
There's a ‘ghost hurricane' in the forecast. It could help predict a real one
A scary-looking weather forecast showing a hurricane hitting the Gulf Coast in the second half of June swirled around social media this week—but don't panic.
It's the season's first 'ghost hurricane.'
Similar hype plays out every hurricane season, especially at the beginning: A cherry-picked, worst-case-scenario model run goes viral, but more often than not, will never come to fruition.
Unofficially dubbed 'ghost storms' or 'ghost hurricanes,' these tropical systems regularly appear in weather models — computer simulations that help meteorologists forecast future conditions — but never seem to manifest in real life.
The model responsible this week was the Global Forecast System, also known as the GFS or American model, run by the National Oceanic and Atmospheric Administration. It's one of many used by forecasters around the world.
All models have known biases or 'quirks' where they tend to overpredict or underpredict certain things. The GFS is known to overpredict tropical storms and hurricanes in longer-term forecasts that look more than a week into the future, which leads to these false alarms. The GFS isn't alone in this — all models struggle to accurately predict tropical activity that far in advance — but it is notorious for doing so.
For example, the GFS could spit out a prediction for a US hurricane landfall about 10 days from now, only to have that chance completely disappear as the forecast date draws closer. This can occur at any time of the year, but is most frequent during hurricane season — June through November.
It's exactly what's been happening over the past week as forecasters keep an eye out for the first storm of the 2025 Atlantic hurricane season.
No weather forecast model is designed in the exact same way as another, and that's why each can generate different results with similar data.
The reason the GFS has more false alarms when looking more than a week out than similar models – like Europe's ECMWF, Canada's CMC or the United Kingdom's UKM – is because that's exactly what it's programmed to do, according to Alicia Bentley, the global verification project lead of NOAA's Environmental Modeling Center.
The GFS was built with a 'weak parameterized cumulus convection scheme,' according to Bentley. In plain language, that means when the GFS thinks there could be thunderstorms developing in an area where tropical systems are possible – over the oceans – it's more likely to jump to the conclusion that something tropical will develop than to ignore it.
Other models aren't built to be quite as sensitive to this phenomenon, and so they don't show a tropical system until they're more confident the right conditions are in place, which usually happens when the forecast gets closer in time.
The western Caribbean Sea is one of the GFS' favorite places to predict a ghost storm. That's because of the Central American gyre: a large, disorganized area of showers and thunderstorms that rotates over the region and its surrounding water.
The combination of abundant moisture and spin in the atmosphere makes it a prime breeding ground for storms, especially early in and during the peak of hurricane season. Given the model's sensitivity, it's quick to pounce on these possible storms.
But this sensitivity has an advantage: By highlighting almost anything that could become tropical, the GFS misses very few actual storms.
Its tendency to cry wolf isn't ideal, but the GFS team found it was worth giving the model a higher chance at catching every storm and better predicting each one's intensity than to prioritize fewer false alarms, Bentley explained.
'It was critical to improve the probability of detection of tropical cyclone formation and tropical cyclone intensity forecasts… and we did achieve that,' Bentley said.
During the 2024 hurricane season, the GFS had the least error when forecasting the intensity of tropical cyclones – tropical depressions, tropical storms and hurricanes – of any other global forecast models in its class: the ECMWF, the CMC and the UKM. However, the ECMWF and UKM outperformed the GFS in tropical track forecasts out more than five days in the future.
Despite how often the GFS conjures ghost systems in its longer term forecasts, it can't be discounted.
'The crucial role of the forecaster is to understand a model's known biases and use that knowledge to their advantage to produce a better forecast,' Bentley said.
Knowing the GFS latches onto anything that could even vaguely become tropical well in advance helps forecasters keep an eye on areas where conditions may ultimately come together to create the next hurricane.
The more reliable solution for predicting tropical behavior more than a few days in advance is to take advantage of ensemble forecasting, according to Bentley.
'A deterministic model like the GFS produces one forecast at a time; it gives one answer,' Bentley explained. 'An ensemble forecast can show you a variety of possible outcomes, as well as which forecast looks like a possible outlier.'
Unlike social media clickbait, no well thought out forecast is made from a single model run. Forecasters use everything at their disposal – deterministic and ensemble models, observations, climatology and more – to predict weather as accurately as possible to give people the time and information they need to stay safe.
The National Hurricane Center, for example, typically uses a blend of different types of models to make their forecasts. That strategy, combined with extensive expertise, led to their most accurate track forecasts on record for the Atlantic last season.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
19 minutes ago
- CBS News
Power outages in New Rochelle, N.Y. due to fallen tree
There are power outages in New Rochelle, New York after a tree fell onto electrical lines. Approximately 150 customers lost power Friday in the area of Beaufort Place, according to Con Edison's outage map. A tree fell at 79 Beaufort Place and took down two overhead poles shortly before 1 p.m., Con Ed said. The utility expected power to be restored within the hour. This is a developing story. Please check for updates.


Fox News
39 minutes ago
- Fox News
Common menopause medication might prevent breast cancer while treating hot flashes
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, "significantly reduced" breast tissue cell growth, which is a major indicator of cancer progression. A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. "The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo," Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. "This would be expected, as the drug is FDA-approved to treat hot flashes." "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer." Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings are preliminary and have not yet been published in a medical journal. "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced "high-risk lesions" — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. "These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options," the release stated. The researchers said they are "encouraged" by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. "Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure," Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. "While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk," she told Fox News Digital. Kabraji also noted that the study focused on reducing levels of one specific protein, "which does not always predict reduced recurrence of breast cancer." "This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer," she noted. "While intriguing, this study is highly preliminary." "Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention." For more Health articles, visit Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. "Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms," she added.


Gizmodo
44 minutes ago
- Gizmodo
‘Star Wars: Starfighter' Adds ‘Frankenstein' Star Mia Goth
As much as we'd love to see a Star Wars movie that just stars Ryan Gosling, Star Wars: Starfighter was never going to be that. He needs co-stars, aliens, droids, and now the very first of those may have come into view. The InSneider reports, and io9 has confirmed, that Mia Goth, the actress best known for her roles in Pearl, X, and MaXXXine, who'll soon appear Guillermo del Toro's Frankenstein and Christopher Nolan's The Odyssey, has been cast in the film. No word on what the role is, but reporter Jeff Sneider writes it is the same one Anora-star and Oscar-winner Mikey Madison was circling before moving along. This story is developing…